Supernus (SUPN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Oculis Holding (OCS – Research Report) today and set a price target of ...

I did not cover the stock, but how should we think about the ramp up of this product and what could be the contribution in the initial stages? Jack Qutar, CEO, Supernus Pharmaceuticals ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $18.00. The ...

I did not cover the stock, but how should we think about the ramp up of this product and what could be the contribution in the initial stages? Jack Qutar, CEO, Supernus Pharmaceuticals: Yes. I mean ...

Explore Supernus Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SUPN. Supernus' SPN-820 Phase 2b study in treatment-resistant depression ...